Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin-etoposide chemoradiotherapy for stage II-III Merkel cell carcinoma
ACTRN12610000480088Phase 2Active, not recruiting
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Jun 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and etoposide in Merkel cell carcinoma (MCC), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoints: Time to locoregional failure and Grade 3-4 toxicity and febrile neutropenia incidence. Started Jun 2010; status: active, not recruiting.
02
Drugs
carboplatinetoposide
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on ACTRN12610000480088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000480088.